Monopar Kicks Off Rolling NDA for ALXN1840 in Wilson Disease

summarizeSummary

Monopar has launched the rolling NDA submission for ALXN1840 in Wilson disease, a pivotal regulatory move that could yield the first new therapy for the condition in decades and a potential Priority Review Voucher.

check_boxKey Events · Product Development and Regulatory · MNPR

• Rolling NDA Submission Initiated

  Under an FDA-authorized rolling review, Monopar has submitted the first completed sections of the NDA for ALXN1840 in Wilson disease.

• Regulatory Designations Support Approval

  ALXN1840 carries Fast Track, Orphan Drug, and Rare Pediatric Disease designations—the latter offering a potential Priority Review Voucher upon approval.

• First-in-Class Potential

  If approved, ALXN1840 would be the first therapy with a novel mechanism of action for Wilson disease in decades, addressing a significant unmet need.

• Timeline on Track

  The initiation aligns with the company's previously stated mid-2026 NDA submission target, demonstrating solid execution on its regulatory strategy.

auto_awesomeAnalysis · MNPR · Life Sciences

A critical regulatory step is underway: Monopar has begun the rolling NDA submission for ALXN1840, its first-in-class Wilson disease therapy. The FDA's green light for a rolling review means completed sections can be evaluated now, potentially shortening the path to approval. With Fast Track, Orphan Drug, and Rare Pediatric Disease designations already in hand, a successful NDA could deliver the first novel treatment for Wilson disease in decades—and a valuable Priority Review Voucher. Trading near its 52-week high, the stock reflects elevated expectations, and this milestone confirms the company is on track with its mid-2026 submission target.